Stabilization of measles virus for vaccine formulation

Human Vaccines

Volumn 4, Issue 5, 2008, Pages 350-359

  Kissmann, Julian ^a   Ausar, Salvador F ^a,f   Rudolph, Angela ^a   Braun, Chad ^b,c   Cape, Stephen P ^c   Sievers, Robert E ^c,d   Federspiel, Mark J ^e   Joshi, Sangeeta B ^a   Middaugh, C Russell ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b ARRAY BIOPHARMA INC   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Aktiv Dry LLC   (United States)

^e MAYO CLINIC   (United States)

^f Sanofi Pasteur   (Canada)

Author keywords

Circular dichroism; Empirical phase diagram; Fluorescence; Formulation; Light scattering; Measles; Stability; Vaccine

Indexed keywords

ALBUMIN; ARGININE; ASCORBIC ACID; ASPARTIC ACID; CALCIUM CHLORIDE; CITRATE SODIUM; CITRIC ACID; DIETHANOLAMINE; GELATIN; GLUCOSE; GLUTAMIC ACID; GLYCEROL; GLYCINE; GUANIDINE; HISTIDINE; INOSITOL; LACTOSE; LYSINE; MALIC ACID; MANNITOL; MEASLES VACCINE; POLIDOCANOL; POLYSORBATE 20; POLYSORBATE 80; PROLINE; SODIUM DIHYDROGEN PHOSPHATE; SORBITOL; SUCROSE; TREHALOSE; UNINDEXED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG STABILITY; TEMPERATURE DEPENDENCE; THERMOSTABILITY; VACCINE PRODUCTION; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS PARTICLE;

EID: 54949139985     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.5.5863     Document Type: Article

References (27)

1. Wolfson LJ, Strebel PM, Gacic-Dobo M, Hoekstra EJ, McFarland JW, Hersh BS. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 2007; 369:191-200.
2. Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR. Thermal stability of vaccines. J Pharm Sci 2003; 92:218-31.
3. Plotkin SA, Orenstein WA. Vaccines. Philadelphia: Saunders 2004.
4. Physicians' desk reference: PDR 2004. Montvale, N.J.: Thomson PDR 2004.
5. Jiang G, Joshi SB, Peek LJ, Brandau DT, Huang J, Ferriter MS, Woodley WD, Ford BM, Mar KD, Mikszta JA, Hwang CR, Ulrich R, Harvey NG, Middaugh CR, Sullivan VJ. Anthrax vaccine powder formulations for nasal mucosal delivery. J Pharm Sci 2006; 95:80-96.
6. Peek LJ, Brandau DT, Jones LS, Joshi SB, Middaugh CR. A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine. Vaccine 2006; 24:5839-51.
7. Ausar SF, Espina M, Brock J, Thyagarayapuran N, Repetto R, Khandke L, Middaugh CR. High-throughput screening of stabilizers for respiratory syncytial virus: identification of stabilizers and their erfects on the conformational thermostability of viral particles. Hum Vac 2007; 3:94-103.
8. Van Holde KE, Johnson WC, Ho PS. Principles of physical biochemistry. Upper Saddle River. N.J.: Pearson/Prentice Hall 2006.
9. Cattaneo R, Rebmann G, Baczko K, ter Meulen V, Billeter MA. Altered ratios of measles virus transcripts in diseased human brains. Virology 1987; 160:523-6.
10. Colf LA, Juo ZS, Garcia KC. Structure of the measles virus hemagglutinin. Nat Struct Mol Biol. 2007; 14:1227-8.
11. Burger JL, Cape SP, Braun CS, Mcadams DH, Best JA, Bhagwat P, Pathak P, Rebits LG, Sievers RE. Stabilizing Formulations for Inhalable Powders of Live-Attenuated Measles Virus Vaccine. J Aerosol Med 2008; 21:25-34.
12. Kendrick BS, Chang BS, Arakawa T, Peterson B, Randolph TW, Manning MC, Carpenter JF. Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: role in restricted conformational mobility and compaction of native state. Proc Natl Acad Sci USA 1997; 94:11917-22.
13. Lee JC, Timasheff SN. The stabilization of proteins by sucrose. J Biol Chem 1981; 256:7193-201.
14. Shimizu S, Smith DJ. Preferential hydration and the exclusion of cosolvents from protein surfaces. J Chem Phys 2004; 121:1148-54.
15. Fields BN, Knipe DM, Howley PM, Griffin DE. Fields' virology. Philadelphia: Lippincott Williams & Wilkins 2001.
16. Lemmon MA, Engelman DM. Specificity and promiscuity in membrane helix interactions. FEBS letters 1994; 346:17-20.
17. Rees DC, DeAntonio L, Eisenberg D. Hydrophobic organization of membrane proteins. Science (New York, NY) 1989; 245:510-3.
18. Evans RK, Nawrocki DK, Isopi LA, Williams DM, Casimiro DR, Chin S, Chen M, Zhu DM, Shiver JW, Volkin DB. Development of stable liquid formulations for adenovirus-based vaccines. J Pharm Sci 2004; 93:2458-75.
19. Schwendeman SP, Costantino HR, Gupta RK, Siber GR, Klibanov AM, Langer R. Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation. Proc Natl Acad Sci USA 1995; 92:11234-8.
20. Volkin DB, Mach H, Middaugh CR. Degradative covalent reactions important to protein stability. Mol Biotechnol 1997; 8:105-22.
21. Wakankar AA, Borchardt RT. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J Pharm Sci 2006; 95:2321-36.
22. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R, Morris JC, Russell SJ. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103:1641-6.
23. Ausar SF, Rexroad J, Frolov VG, Look JL, Konar N, Middaugh CR. Analysis of the thermal and pH stability of human respiratory syncytial virus. Mol Pharm 2005; 2:491-9.
24. Lakowicz JR. Principles of fluorescence spectroscopy. New York: Kluwer Academic/Plenum 1999.
25. Parasassi T, De Stasio G, Ravagnan G, Rusch RM, Gratton E. Quantitation of lipid phases in phospholipid vesicles by the generalized polarization of Laurdan fluorescence. Biophys J 1991; 60:179-89.
26. Kueltzo LA, Ersoy B, Ralston JP, Middaugh CR. Derivative absorbance spectroscopy and proteins phase diagrams as tools for comprehensive protein characterization; a bGCSF case study. J Pharm Sci 2003; 92:1805-20.
27. Schrag SJ, Rota PA, Bellini WJ. Spontaneous mutation rate of measles virus: direct estimation based on mutations conferring monoclonal antibody resistance. J Virol 1999; 73:51-4.